PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure
Executive Summary
Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.